Camena Bioscience Raises £7.8M to Expand Synthetic Gene Operations
Camena Bioscience, a Cambridge, UK-based provider of synthetic genes to the pharmaceutical and biotechnology industries, recently announced that it has raised £7.8M in Series A funding. This funding round was led by Mercia Ventures, a renowned investment firm specializing in early-stage technology companies. In addition to Mercia Ventures, the board of Camena Bioscience will now include Aditya Rajagopal and Lee Lindley, both highly experienced professionals in their respective fields.
The primary goal of this funding is to enable Camena Bioscience to scale its operations and further develop its groundbreaking DNA synthesis platform known as gSynth.
Co-founded by CEO Steve Harvey and CSO Derek Stemple, the company has pioneered an enzyme-based DNA synthesis technology that aims to overcome the limitations of traditional DNA synthesis methods. By employing this innovative approach, Camena Bioscience can produce synthetic DNA with superior accuracy and efficiency.
Camena Bioscience has already positioned itself as a key player in the industry, having signed commercial agreements with several leading biotech and pharmaceutical companies. These agreements have not only boosted its credibility, but have also secured a substantial multi-million pound revenue stream for the company. With the recent injection of funds, Camena Bioscience is poised to solidify its position as a market leader and continue driving innovation in the field of synthetic gene production.
Click here for a full list of 6,528+ startup investors in the UK